Gaps in childhood immunizations and preventive care visits during the COVID-19 pandemic: a population-based cohort study of children in Ontario and Manitoba, Canada, 2016-2021.

OBJECTIVE: We aimed to estimate the changes to the delivery of routine immunizations and well-child visits through the pandemic. METHODS: Using linked administrative health data in Ontario and Manitoba, Canada (1 September 2016 to 30 September 2021), infants <12 months old (N=291,917 Ontario, N=33,994 Manitoba) and children between 12 and 24 months old (N=293,523 Ontario, N=33,001 Manitoba) exposed and unexposed to the COVID-19 pandemic were compared on rates of receipt of recommended a) vaccinations and b) well-child visits after adjusting for sociodemographic measures. In Ontario, vaccinations were captured using physician billings database, and in Manitoba they were captured in a centralized vaccination registry. RESULTS: Exposed Ontario infants were slightly more likely to receive all vaccinations according to billing data (62.5% exposed vs. 61.6% unexposed; adjusted Relative Rate (aRR) 1.01 [95% confidence interval (CI) 1.00-1.02]) whereas exposed Manitoba infants were less likely to receive all vaccines (73.5% exposed vs. 79.2% unexposed; aRR 0.93 [95% CI 0.92-0.94]). Among children exposed to the pandemic, total vaccination receipt was modestly decreased compared to unexposed (Ontario aRR 0.98 [95% CI 0.97-0.99]; Manitoba aRR 0.93 [95% CI 0.91-0.94]). Pandemic-exposed infants were less likely to complete all recommended well-child visits in Ontario (33.0% exposed, 48.8% unexposed; aRR 0.67 [95% CI 0.68-0.69]) and Manitoba (55.0% exposed, 70.7% unexposed; aRR 0.78 [95% CI 0.77-0.79]). A similar relationship was observed for rates of completed well-child visits among children in Ontario (aRR 0.78 [95% CI 0.77-0.79]) and Manitoba (aRR 0.79 [95% CI 0.77-0.80]). CONCLUSION: Through the first 18 months of the pandemic, routine vaccines were delivered to children < 2 years old at close to pre-pandemic rates. There was a high proportion of incomplete well-child visits, indicating that developmental surveillance catch-up is crucial.

RéSUMé: OBJECTIF: Nous avons voulu estimer les changements dans l'administration des vaccins de routine et dans les consultations pédiatriques pendant la pandémie. MéTHODE: À l'aide des données administratives sur la santé couplées de l'Ontario et du Manitoba, au Canada (1er septembre 2016 au 30 septembre 2021), nous avons comparé les taux de réception : a) des vaccins recommandés et b) des consultations pédiatriques recommandées pour les nourrissons de < 12 mois (N = 291 917 en Ontario, N = 33 994 au Manitoba) et pour les enfants de 12 à 24 mois (N = 293 523 en Ontario, N = 33 001 au Manitoba) exposés et non exposés à la pandémie de COVID-19, après ajustement en fonction de mesures sociodémographiques. En Ontario, les vaccins ont été saisis à l'aide de la base de données des factures des médecins; au Manitoba, ils ont été saisis dans un registre de vaccination centralisé. RéSULTATS: Les nourrissons exposés en Ontario étaient légèrement plus susceptibles de recevoir tous les vaccins selon les données de facturation (62,5 % pour les nourrissons exposés c. 61,6 % pour les nourrissons non exposés; risque relatif ajusté [RRa] 1,01 [intervalle de confiance (IC) de 95 % 1,00-1,02]), tandis que les nourrissons exposés au Manitoba étaient moins susceptibles de recevoir tous les vaccins (73,5 % pour les nourrissons exposés c. 79,2 % pour les nourrissons non exposés; RRa 0,93 [IC de 95 % 0,92-0,94]). Chez les enfants exposés à la pandémie, le total des vaccins reçus était un peu plus faible que chez les enfants non exposés (RRa en Ontario 0,98 [IC de 95 % 0,97-0,99]; RRa au Manitoba 0,93 [IC de 95 % 0,91-0,94]). Les nourrissons exposés à la pandémie étaient moins susceptibles d'avoir eu toutes les consultations pédiatriques recommandées en Ontario (33 % pour les nourrissons exposés, 48,8 % pour les nourrissons non exposés; RRa 0,67 [IC de 95 % 0,68-0,69]) comme au Manitoba (55 % pour les nourrissons exposés, 70,7 % pour les nourrissons non exposés; RRa 0,78 [IC de 95 % 0,77-0,79]). Une relation semblable a été observée pour les taux de consultations pédiatriques complètes chez les enfants en Ontario (RRa 0,78 [IC de 95 % 0,77-0,79]) et au Manitoba (RRa 0,79 [(IC de 95 % 0,77-0,80]). CONCLUSION: Au cours des 18 premiers mois de la pandémie, les vaccins de routine ont été administrés aux enfants de < 2 ans à des taux proches de ceux d'avant la pandémie. Il y a eu une forte proportion de consultations pédiatriques incomplètes, ce qui indique qu'il est essentiel de rattraper la surveillance du développement.

Acute mental health service use following onset of the COVID-19 pandemic in Ontario, Canada: a trend analysis.

BACKGROUND: The extent to which heightened distress during the COVID-19 pandemic translated to increases in severe mental health outcomes is unknown. We examined trends in psychiatric presentations to acute care settings in the first 12 months after onset of the pandemic. METHODS: This was a trends analysis of administrative population data in Ontario, Canada. We examined rates of hospitalizations and emergency department visits for mental health diagnoses overall and stratified by sex, age and diagnostic grouping (e.g., mood disorders, anxiety disorders, psychotic disorders), as well as visits for intentional self-injury for people aged 10 to 105 years, from January 2019 to March 2021. We used Joinpoint regression to identify significant inflection points after the onset of the pandemic in March 2020. RESULTS: Among the 12 968 100 people included in our analysis, rates of mental health-related hospitalizations and emergency department visits declined immediately after the onset of the pandemic (peak overall decline of 30% [hospitalizations] and 37% [emergency department visits] compared to April 2019) and returned to near prepandemic levels by March 2021. Compared to April 2019, visits for intentional self-injury declined by 33% and remained below prepandemic levels until March 2021. We observed the largest declines in service use among adolescents aged 14 to 17 years (55% decline in hospitalizations, 58% decline in emergency department visits) and 10 to 13 years (56% decline in self-injury), and for those with substance-related disorders (33% decline in emergency department visits) and anxiety disorders (61% decline in hospitalizations). INTERPRETATION: Contrary to expectations, the abrupt decline in acute mental health service use immediately after the onset of the pandemic and the return to near prepandemic levels that we observed suggest that changes and stressors in the first 12 months of the pandemic did not translate to increased service use. Continued surveillance of acute mental health service use is warranted.

Substance use and related harms in the context of COVID-19: a conceptual model. / Consommation de substances et méfaits connexes dans le contexte de la COVID-19 : un modèle conceptuel.

As the effects of COVID-19 have been unfolding, growing attention has been paid to the intersection of COVID-19 and substance use and the related harms. However, there are few theories and little empirical evidence to guide investigations in this area. To advance this emerging area of inquiry, we present a conceptual model that synthesizes evidence, information and knowledge on substance use and related harms in the context of the pandemic. The conceptual model offers a visual representation of the connections between the pandemic and substance use and related harms, and can be used to identify areas for future research.

As of June 2020, substance use and related harms in the context of a pandemic remained largely uninvestigated. The COVID-19 pandemic may impact how Canadians use substances and may present specific challenges and harms among people who use substances. The conceptual model in this paper offers a synthesis of evidence, information and knowledge of the concepts and associations relevant to substance use and harms in the context of the pandemic. Relevant concepts were synthesized into five interrelated domains that can be used to identify areas for future research into substance use and related harms in the context of COVID-19: substance use as a means of coping; changes in social support and networks; availability and accessibility of services; increased risk of COVID-19 transmission among people who use substances; and increased risk of severe outcomes.

En juin 2020, la consommation de substances et les méfaits connexes dans le contexte de la pandémie restaient largement inexplorés. La pandémie de COVID-19 peut avoir une incidence sur la façon dont les Canadiens consomment des substances, ce qui pourrait entraîner des défis et des méfaits particuliers chez ces personnes. Le modèle conceptuel présenté dans le présent document offre une synthèse des données probantes, de l'information et des connaissances sur les concepts et les associations relatifs à la consommation de substances et aux méfaits dans le contexte de la pandémie. Les concepts pertinents ont été synthétisés en cinq domaines interreliés qui peuvent être utilisés pour déterminer les futurs domaines de recherche sur la consommation de substances et les méfaits connexes dans le contexte de la COVID-19, soit la consommation de substances comme stratégie d'adaptation, les changements relatifs au soutien social et aux réseaux; la disponibilité et l'accessibilité des services; le risque accru de transmission de la COVID-19 chez les personnes qui consomment des substances; et le risque accru de conséquences graves.

Efficacy of bacterial vaccines to prevent respiratory disease in swine: a systematic review and network meta-analysis.

A systematic review and network meta-analysis (MA) was conducted to address the question, 'What is the efficacy of bacterial vaccines to prevent respiratory disease in swine?' Four electronic databases and the grey literature were searched to identify clinical trials in healthy swine where at least one intervention arm was a commercially available vaccine for one or more bacterial pathogens associated with respiratory disease in swine, including Mycoplasma hyopneumoniae, Actinobacillus pleuropneumonia, Actinobacillus suis, Bordetella bronchiseptica, Pasteurella multocida, Stretococcus suis, Haemophils parasuis, and Mycoplasma hyorhinis. To be eligible, trials had to measure at least one of the following outcomes: incidence of clinical morbidity, mortality, lung lesions, or total antibiotic use. There were 179 eligible trials identified in 146 publications. Network MA was undertaken for morbidity, mortality, and the presence or absence of non-specific lung lesions. However, there was not a sufficient body of research evaluating the same interventions and outcomes to allow a meaningful synthesis of the comparative efficacy of the vaccines. To build this body of research, additional rigor in trial design and analysis, and detailed reporting of trial methods and results are warranted.

A systematic review of the efficacy of antibiotics for the prevention of swine respiratory disease.

Prevention and control of respiratory disease is a major contributor to antibiotic use in swine. A systematic review was conducted to address the question, 'What is the comparative efficacy of antimicrobials for the prevention of swine respiratory disease?' Eligible studies were controlled trials published in English evaluating prophylactic antibiotics in swine, where clinical morbidity, mortality, or total antibiotic use was assessed. Four databases and the gray literature were searched for relevant articles. Two reviewers working independently screened titles and abstracts for eligibility followed by full-text articles, and then extracted data and evaluated risk of bias for eligible trials. There were 44 eligible trials from 36 publications. Clinical morbidity was evaluated in eight trials where antibiotics were used in nursery pigs and 10 trials where antibiotics were used in grower pigs. Mortality was measured in 22 trials in nursery pigs and 12 trials in grower pigs. There was heterogeneity in the antibiotic interventions and comparisons published in the literature; thus, there was insufficient evidence to allow quantification of the efficacy, or relative efficacy, of antibiotic interventions. Concerns related to statistical non-independence and quality of reporting were noted in the included trials.

The efficacy of antibiotics to control colibacillosis in broiler poultry: a systematic review.

The objective of this systematic review was to evaluate the efficacy of antibiotics to prevent or control colibacillosis in broilers. Studies found eligible were conducted controlled trials in broilers that evaluated an antibiotic intervention, with at least one of the following outcomes: mortality, feed conversion ratio (FCR), condemnations at slaughter, or total antibiotic use. Four electronic databases plus the gray literature were searched. Abstracts were screened for eligibility and data were extracted from eligible trials. Risk of bias was evaluated.Seven trials reported eligible outcomes in a format that allowed data extraction; all reported results for FCR and one also reported mortality. Due to the heterogeneity in the interventions and outcomes evaluated, it was not feasible to conduct meta-analysis.Qualitatively, for FCR, comparisons between an antibiotic and an alternative product did not show a significant benefit for either. Some of the comparisons between an antibiotic and a no-treatment placebo showed a numerical benefit to antibiotics, but with wide confidence intervals. The risk-of-bias assessment revealed concerns with reporting of key trial features.The results of this review do not provide compelling evidence for or against the efficacy of antibiotics for the control of colibacillosis.

The efficacy of litter management strategies to prevent morbidity and mortality in broiler chickens: a systematic review and network meta-analysis.

A systematic review and network meta-analysis (NMA) were conducted to address the question, 'What is the efficacy of litter management strategies to reduce morbidity, mortality, condemnation at slaughter, or total antibiotic use in broilers?' Eligible studies were clinical trials published in English evaluating the efficacy of litter management in broilers on morbidity, condemnations at slaughter, mortality, or total antibiotic use. Multiple databases and two conference proceedings were searched for relevant literature. After relevance screening and data extraction, there were 50 trials evaluating litter type, 22 trials evaluating litter additives, 10 trials comparing fresh to re-used litter, and six trials evaluating floor type. NMAs were conducted for mortality (61 trials) and for the presence or absence of footpad lesions (15 trials). There were no differences in mortality among the litter types, floor types, or additives. For footpad lesions, peat moss appeared beneficial compared to straw, based on a small number of comparisons. In a pairwise meta-analysis, there was no association between fresh versus used litter on the risk of mortality, although there was considerable heterogeneity among studies (I2 = 66%). There was poor reporting of key design features in many studies, and analyses rarely accounted for non-independence of observations within flocks.